© 2022 MJH Life Sciences and Modern Retina. All rights reserved.
© 2022 MJH Life Sciences™ and Modern Retina. All rights reserved.
August 19, 2021
Findings from the Archway trial showed that the PDS effect is long-lasting, consistent, and comparable to those seen with monthly injections.
August 06, 2021
Outlook Therapeutics completes Phase 3 NORSE TWO safety and efficacy trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for treatment of wet AMD.
August 02, 2021
If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.
July 29, 2021
Investigators have found that 78% of neovascular AMD cases have been detected using the PHP home monitoring system.
June 25, 2021
If approved, PDS ranibizumab would become the first and only eye implant with continuous drug delivery, offering an alternative to more frequent anti-VEGF injections for people with wet AMD.
June 23, 2021
Investigators corroborate the hypothesis that retinal ganglion cells with dendrites stratified in the off sublaminae could be damaged.
June 17, 2021
Amid pandemic, physicians and patients have embraced remote technology.
June 15, 2021
An updated PDS procedure reduces complications.
June 07, 2021
The not-for-profit vision and healthcare organization breaks ground on premier Technology Center for assistive technology for people with vision loss.
May 31, 2021
The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.